The enhancement of @entity1370 by concomitant administration of XXXX and @entity7187 .

@entity137 @entity7652 @entity5322 @entity4581 @entity4580 @entity9493 @entity7187 @entity1370
As is well-known, @entity9493 plays an essential role in phase III repolarization of cardiac action potentials. Blocking of @entity9493 channels can lead to LQTS. Inhibition of the metabolism of CYPs activities may elevate plasma levels, to further increase accumulation of drug on cardiac. The elevated serum levels may however elicit unexpected @entity137 . Therefore, the inhibition tests of @entity9493 and CYP are central to the preclinical studies because they may lead to severe @entity1370 . @entity7652 is widely used as an antibacterial agent and often combined with @entity7187 to treat gastropathy. Our objective was to assess @entity1370 during the combined use of @entity7652 with @entity7187 . (1) @entity4580 reduced @entity9493 currents by accelerated channel inactivation. (2) The combination of @entity7652 with @entity4580 reduced @entity9493 currents, producing an inhibitive effect stronger than use of a single drug alone, due to the high binding affinity for the onset of inactivation. (3) When cells were perfused concomitantly with @entity7652 and @entity4581 , they showed a stronger inhibitive effect on @entity9493 currents by decreasing the time constant for the onset of inactivation. (4) The combined administration of @entity7652 with @entity4581 had a powerful inhibitive effect on @entity5322 activities than use of a single drug alone. Collectively, these results demonstrated that concomitant use of @entity7652 with @entity7187 may require close monitoring because of potential @entity137 , especially @entity1370 .
